Psych Congress 2015


SAN DIEGO—Richard Shelton, MD, explains the science behind the obesity/depression connection and offers practical tips for changing patients' diets.

Researchers presented their findings at a poster session at the 28th Annual U.S. Psychiatric and Mental Health Congress.

SAN DIEGO—While the medical literature has done a thorough job of addressing the clinical and legal aspects of psychopharmacology, in one area it has been relatively silent: the ethical issues.

SAN DIEGO—Despite the seeming stagnation in development of therapies for major depression, novel interventions are on the horizon. Dr. Raison identified and explained these upcoming therapies in his pre-conference presentation at the 28th Annual U.S. Psychiatric and Mental Health Congress.

SAN DIEGO—Christoph Correll, MD, explained the difficulties involved in treating patients with severe mental illness and metabolic syndrome, and he outlined some best practices for clinicians.



Psychedelic compounds are powerful, and they have great potential to help patients with intractable conditions. Yet any compound with that kind of power also has the potential to harm, and that harm should not be trivialized.

Personal reports from treatment subjects are as compelling as the quantitative data.

The idea of using these drugs as catalysts for psychotherapeutic change challenges biological psychiatry’s predominant orientation towards mental disease as something that is managed or palliated, but not cured.